1. A regulatory authority’s opinion about surrogate endpoints;Temple,1995
2. US Department of Health and Human Services: FDA: The Nation’s Premier Consumer Health Protection Agency, in US Food and Drug Administration, 2004. Available at: http://www.fda.gov/oc/opacom/brochure/Healthbro.pdf FDA 01-1316. Accessed November 1, 2006
3. US Department of Health and Human Services: Guidance for Industry: Fast Track Drug Development Programs—Designation, Development, and Application Review, in, Food and Drug Administration, 2004. Available at: http://www.fda.gov/cder/guidance/index.htm. Accessed November 1, 2006
4. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients;Chertow;Kidney Int,2002
5. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis;Huybrechts;Value Health,2005